No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

byTeddy Guo

December 21, 2021

in StudyGraphics

Reading Time: 1 min read

Nivolumab did not improve overall survival in patients with advanced hepatocellular carcinoma

RelatedReports

Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening

Oncology

Atezolizumab may improve disease-free survival in mismatch repair deficiency locally advanced colon cancer

April 8, 2026

Eczema more prevalent among older adults than previously thought

Cardiology

Atopic dermatitis activity is not associated with cardiovascular risk

April 2, 2026

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

All Specialties

Oral remibrutinib hits Phase 3 primary endpoint for inducible hives

March 5, 2026

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence

Oncology

Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer

January 28, 2026

Nivolumab may be effective in platinum-resistant ovarian cancer

Nedaplatin-based concurrent chemoradiotherapy is noninferior to cisplatin-based therapy in patients with locoregional nasopharyngeal carcinoma

Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease

Quantitative flow ratio-guided coronary intervention reduces the rate of major cardiac events compared to visual angiography

Many new pediatric asthma cases attributable to obesity

Once-a-week cagrilintide is effective for weight management in overweight and obese patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports